The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis.
Chi-Lun TsaiChih-Cheng LaiChing-Yi ChenHo-Sheng LeePublished in: Expert review of anti-infective therapy (2022)
C5a inhibitors could help reduce the risk of mortality in patients with severe COVID-19 infection while being as safe as placebos. These findings support the promising role of C5a inhibitors in the treatment of severe COVID-19.